Clinical trial shows gene editing works for β-Thalassaemia, too

Researchers have made significant strides in gene editing, particularly with the CRISPR/Cas9 system, which has long been recognized for its potential in targeted genetic modifications. Despite its discovery decades ago, the journey toward safe human applications has been gradual. The first CRISPR-based therapy was approved by the FDA just over two years ago, specifically for treating sickle-cell anemia. Building on this milestone, a collaborative effort in China has introduced an enhanced gene editing technique that promises more precise alterations with fewer errors. This innovative approach has been successfully applied to develop a therapy for β-Thalassaemia, a condition closely related to sickle-cell anemia. The CRISPR/Cas9 mechanism, originally a bacterial defense system, employs specially designed RNAs known as guide RNAs to target specific DNA sequences. The Cas-9 protein then identifies this structure and makes cuts in the DNA. This strategy effectively neutralizes DNA viruses, but it also opens up avenues for editing genetic material in higher organisms, including humans. In the editing process, the cell's natural DNA repair mechanisms often process these cuts, leading to small deletions that can disable genes. The challenge lies in ensuring that these deletions do not cause additional harm, which requires careful DNA sequencing. Alternatively, if a corresponding sequence exists on the other chromosome, cells can sometimes repair the cut using this template. When combined with modified sequences, it enables the introduction of precise edits into the genome. However, the inherent risks of error necessitate extensive cell editing and sequencing to confirm accurate changes.